Key facts
- It has raised $358.0M across 1 recorded rounds; the latest was Early Stage VC ($40.7M) in Apr 2026.
- Notable investors include RA Capital Management, OrbiMed, Novo Holdings, Osage University Partners, Cormorant Asset Management — 10 tracked in total.
- Terremoto Biosciences has filed 1 Form D with the SEC, most recently Apr 2026 ($40.7M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Terremoto Biosciences
Funding rounds
1 roundsAbout Terremoto Biosciences
Developer of a drug development platform designed for small-molecule medicines. The company's platform delivers medicines with optimized clinical profiles, superior therapeutic benefits, and cures for diseases, enabling healthcare sector businesses to improve current medicines and create new therapies with optimized clinical profiles.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2021
- Employees
- 54
- Website
- terremotobio.com/
- Ownership
- Privately Held (backing)
Terremoto Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Terremoto Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Terremoto Biosciences in its N-PORT filings yet. We sweep new filings monthly.